Dan Ilya Piraner, Mohamad H Abedi, Maria J Duran Gonzalez, Adam Chazin-Gray, Iowis Zhu, Pavithran T Ravindran, Thomas Schlichthaerle, Buwei Huang, David Lee, David Baker, Kole T Roybal
{"title":"Engineered Receptors for Soluble Cell-to-Cell Communication","authors":"Dan Ilya Piraner, Mohamad H Abedi, Maria J Duran Gonzalez, Adam Chazin-Gray, Iowis Zhu, Pavithran T Ravindran, Thomas Schlichthaerle, Buwei Huang, David Lee, David Baker, Kole T Roybal","doi":"10.1101/2024.09.17.613377","DOIUrl":null,"url":null,"abstract":"Despite recent advances in mammalian synthetic biology, there remains a lack of modular synthetic receptors that can robustly respond to soluble ligands and in turn activate cellular functions. Such receptors would have extensive clinical potential to regulate the activity of engineered therapeutic cells, but to date only receptors against cell surface targets have approached clinical translation. To address this gap, we developed a receptor based on SynNotch, called synthetic intramembrane proteolysis receptors (SNIPRs), that have the added ability to be activated by soluble ligands, both natural and synthetic, with remarkably low baseline activity and high fold activation. SNIPRs are able to access an endocytic, pH-dependent cleavage mechanism to achieve soluble ligand sensing, in addition to employing a canonical-like pathway for detecting surface-bound ligands. We demonstrate the therapeutic capabilities of the receptor platform by localizing the activity of CAR T-cells to solid tumors where soluble disease-associated factors are expressed, bypassing the major hurdle of on-target off-tumor toxicity in bystander organs. We further applied the SNIPR platform to engineer fully synthetic signaling networks between cells orthogonal to natural signaling pathways, expanding the scope of synthetic biology. Our design framework enables cellular communication and environmental interactions, extending the capabilities of synthetic cellular networking in clinical and research contexts.","PeriodicalId":501308,"journal":{"name":"bioRxiv - Bioengineering","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv - Bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.17.613377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Despite recent advances in mammalian synthetic biology, there remains a lack of modular synthetic receptors that can robustly respond to soluble ligands and in turn activate cellular functions. Such receptors would have extensive clinical potential to regulate the activity of engineered therapeutic cells, but to date only receptors against cell surface targets have approached clinical translation. To address this gap, we developed a receptor based on SynNotch, called synthetic intramembrane proteolysis receptors (SNIPRs), that have the added ability to be activated by soluble ligands, both natural and synthetic, with remarkably low baseline activity and high fold activation. SNIPRs are able to access an endocytic, pH-dependent cleavage mechanism to achieve soluble ligand sensing, in addition to employing a canonical-like pathway for detecting surface-bound ligands. We demonstrate the therapeutic capabilities of the receptor platform by localizing the activity of CAR T-cells to solid tumors where soluble disease-associated factors are expressed, bypassing the major hurdle of on-target off-tumor toxicity in bystander organs. We further applied the SNIPR platform to engineer fully synthetic signaling networks between cells orthogonal to natural signaling pathways, expanding the scope of synthetic biology. Our design framework enables cellular communication and environmental interactions, extending the capabilities of synthetic cellular networking in clinical and research contexts.
尽管哺乳动物合成生物学取得了最新进展,但仍缺乏能对可溶性配体做出强有力反应并进而激活细胞功能的模块化合成受体。这种受体在调节工程治疗细胞的活性方面具有广泛的临床潜力,但迄今为止,只有针对细胞表面靶点的受体已接近临床转化。为了填补这一空白,我们开发了一种基于 SynNotch 的受体,称为合成膜内蛋白水解受体(SNIPRs),这种受体还能被天然和合成的可溶性配体激活,基线活性极低,激活倍数极高。SNIPRs 除了采用类似于典范的途径检测表面结合配体外,还能通过内吞、pH 依赖性裂解机制实现可溶性配体感应。我们通过将 CAR T 细胞的活性定位到表达可溶性疾病相关因子的实体瘤上,证明了该受体平台的治疗能力,从而绕过了旁观器官的靶向非肿瘤毒性这一主要障碍。我们进一步应用 SNIPR 平台,在细胞间设计出与自然信号通路正交的全合成信号网络,从而扩大了合成生物学的范围。我们的设计框架实现了细胞通信和环境互动,拓展了合成细胞网络在临床和研究方面的能力。